These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12396862)

  • 1. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A.
    Kranz G; Sycha T; Voller B; Kranz GS; Schnider P; Auff E
    Neurology; 2008 Jan; 70(2):133-6. PubMed ID: 18180443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A.
    Voller B; Moraru E; Auff E; Benesch M; Poewe W; Wissel J; Müller J; Entner T; Bigalke H; Schnider P
    Mov Disord; 2004 Aug; 19(8):943-7. PubMed ID: 15300661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.
    Birklein F; Walther D; Bigalke H; Winterholler M; Erbguth F
    Ann Neurol; 2002 Jul; 52(1):68-73. PubMed ID: 12112049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
    Sankhla C; Jankovic J; Duane D
    Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR
    J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.
    Göschel H; Wohlfarth K; Frevert J; Dengler R; Bigalke H
    Exp Neurol; 1997 Sep; 147(1):96-102. PubMed ID: 9294406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
    Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure.
    Schulte-Baukloh H; Bigalke H; Miller K; Heine G; Pape D; Lehmann J; Knispel HH
    Int J Urol; 2008 May; 15(5):407-15; discussion 415. PubMed ID: 18452456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
    Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
    Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test.
    Cordivari C; Misra VP; Vincent A; Catania S; Bhatia KP; Lees AJ
    Mov Disord; 2006 Oct; 21(10):1737-41. PubMed ID: 16874756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of resistance to botulinum toxin type A in patients with torticollis.
    Greene P; Fahn S; Diamond B
    Mov Disord; 1994 Mar; 9(2):213-7. PubMed ID: 8196686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.